Dialysis · Hemodialysis TechniqueDialysis · Teknik ng HemodialysisDialysis · Teknik sa HemodialysisDialysis · Teknik ning Hemodialysis

Is Hemodiafiltration the New Standard?Ang Hemodiafiltration na ba ang Bagong Pamantayan?Ang Hemodiafiltration na ba ang Bag-ong Sukaranan?Ing Hemodiafiltration na ya ing Bayung Pamantayan?

What the newest trials show about high-volume HDF, who it fits, and what to ask your dialysis unit before switching.Ang ipinapakita ng pinakabagong pag-aaral tungkol sa high-volume HDF, kanino ito angkop, at ano ang itatanong sa iyong dialysis unit bago lumipat.Ang gipakita sa labing bag-ong mga pagtuon bahin sa high-volume HDF, kang kinsa kini haom, ug unsay pangutan-on sa imong dialysis unit sa dili pa mobalhin.Ing pepakit dareng pekabayung pag-aral tungkul king high-volume HDF, nanu ing angkup kaniti, at nanu ing kutnan king dialysis unit mu bayu ka lumipat.

Summary

Evidence. In adults able to receive at least 23 L of convection per session, high-volume post-dilution hemodiafiltration (HDF) lowered all-cause mortality versus high-flux hemodialysis (HD) in CONVINCE (hazard ratio 0.77), consistent with pooled trials (hazard ratio 0.84); hospitalizations did not fall.

Guidance. The Italian Society of Nephrology (2026) recommends HDF to reduce cardiovascular mortality (strong, moderate certainty) and suggests high-volume HDF for all-cause mortality.

Practice. Offer it where the unit produces ultrapure substitution fluid and audits delivered volume; never raise net ultrafiltration to reach the target. High-flux HD remains appropriate otherwise. Philippine Health Insurance Corporation (PhilHealth) lists HDF as a disclosed premium above its ₱6,350 session benefit.

PublishedNailathalaGipatikPepalwal: ReferencesMga SanggunianMga TinubdanReng Reperensya: 18 Read timeOras ng pagbasaOras sa pagbasaOras ning pamamasa:
Last ReviewedHuling Na-reviewKatapusang Na-reviewKarinan Na-review:
A Filipino woman in her fifties seated in a dialysis chair talks with her nephrologist, who points to the convection volume shown on a hemodiafiltration machine screen
💡

The one-minute answerAng sagot sa isang minutoAng tubag sa usa ka minutoIng sagot king metung a minutu

Hemodiafiltration (HDF) is a form of hemodialysis that adds a second way of cleaning the blood, so it removes more of the larger waste molecules. In the largest trial, adults who received high-volume HDF were less likely to die over about two and a half years than adults who stayed on standard high-flux hemodialysis (HD). That trial enrolled people whose teams expected them to receive a large HDF volume at almost every session. So HDF is a strong option when your unit can deliver it well, safely, and consistently, and when you want it. Good high-flux HD is still proper treatment if HDF is unavailable, unaffordable, or cannot be given reliably to you.Ang hemodiafiltration (HDF) ay isang uri ng hemodialysis na nagdadagdag ng ikalawang paraan ng paglilinis ng dugo, kaya mas maraming malalaking dumi ang natatanggal. Sa pinakamalaking pag-aaral, ang mga nasa hustong gulang na tumanggap ng high-volume HDF ay mas kaunti ang namatay sa loob ng mga dalawa at kalahating taon kumpara sa mga nanatili sa karaniwang high-flux hemodialysis (HD). Ang mga isinama sa pag-aaral ay mga taong inaasahan ng kanilang team na makakatanggap ng malaking volume ng HDF halos bawat session. Kaya malakas na opsyon ang HDF kapag kaya ng iyong unit na ibigay ito nang maayos, ligtas, at tuloy-tuloy, at kapag gusto mo ito. Tamang gamutan pa rin ang maayos na high-flux HD kung walang HDF, hindi kaya ang gastos, o hindi ito maibibigay nang maaasahan sa iyo.Ang hemodiafiltration (HDF) usa ka matang sa hemodialysis nga nagdugang og ikaduhang paagi sa paglimpyo sa dugo, busa mas daghang dagkong hugaw ang makuha. Sa kinadak-ang pagtuon, ang mga hamtong nga nakadawat og high-volume HDF mas gamay ang namatay sulod sa mga duha ug tunga ka tuig kaysa sa mga nagpabilin sa naandang high-flux hemodialysis (HD). Ang gilakip sa pagtuon mao ang mga tawo nga gilauman sa ilang team nga makadawat og dakong volume sa HDF halos matag session. Busa lig-on nga kapilian ang HDF kung kaya sa imong unit nga ihatag kini nga maayo, luwas, ug padayon, ug kung gusto nimo kini. Husto gihapon nga pagtambal ang maayong high-flux HD kung walay HDF, dili kaya ang gasto, o dili kini mahatag kanimo nga kasaligan.Ing hemodiafiltration (HDF) metung yang klasi ning hemodialysis a mamandagdag ikaduang paralan ning pamaglinis king daya, anya mas dakal a maragul a dumi ing maalis. King pekamaragul a pag-aral, ding matua a tinggap high-volume HDF mas kakaunti ing mete king lub ning adwang taun at kalahati nung ikumpara karing menatili king karaniwan a high-flux hemodialysis (HD). Ding tau king pag-aral, ila reng aasahan ning team da a makatanggap maragul a volume ning HDF malapit balang session. Anya matibe yang opsyon ing HDF nung kaya ning unit mu ing ibie ya mayap, ligtas, at tuloy-tuloy, at nung buri mu ya. Tamang panulu ya pa murin ing mayap a high-flux HD nung ala yang HDF, e kaya ing gastus, o e ya maibie keka a maasahan.

Is HDF the new standard?Ang HDF na ba ang bagong pamantayan?Ang HDF na ba ang bag-ong sukaranan?Ing HDF na ya ing bayung pamantayan?

For adults on dialysis three times a week in a dialysis center, many kidney experts now treat high-volume HDF as a reasonable preferred option when it can be done well. It is not yet a must-have for everyone. Here is the main result in plain numbers.Para sa mga nasa hustong gulang na nagda-dialysis tatlong beses isang linggo sa dialysis center, maraming eksperto sa bato ang itinuturing na ngayon ang high-volume HDF bilang makatwirang mas pinipiling opsyon kapag maayos itong magagawa. Hindi pa ito kailangang-kailangan ng lahat. Narito ang pangunahing resulta sa simpleng numero.Alang sa mga hamtong nga nagpa-dialysis tulo ka beses sa usa ka semana sa dialysis center, daghang eksperto sa kidney karon ang nag-isip sa high-volume HDF isip makatarunganong mas gipili nga kapilian kung mahimo kini nga maayo. Dili pa kini kinahanglanon sa tanan. Ania ang nag-unang resulta sa yanong numero.Para karing matua a mag-dialysis makatlu king metung a dominggu king dialysis center, dakal a eksperto king batu ngeni ing ituturing da ing high-volume HDF bilang makatwiran a mas pipiliang opsyon nung agawa yang mayap. E pa ya kailangan ning sablang tau. Oyni ing pekamaulagang resulta king simpling numeru.

🔍

What these numbers do and do not sayAng sinasabi at hindi sinasabi ng mga numerong itoAng gisulti ug wala gisulti niining mga numeroIng sasabyan at e sasabyan dareng numerung reni

They come from people who were already stable on dialysis for at least three months and who could reach a high HDF volume. They do not tell us what happens in people whose access or blood pressure keeps the volume low, in people dialyzing twice a week, or in children. The study also did not show fewer hospital stays.Galing ang mga ito sa mga taong stable na sa dialysis nang hindi bababa sa tatlong buwan at kayang umabot sa mataas na volume ng HDF. Hindi nito sinasabi kung ano ang mangyayari sa mga taong ang access o presyon ng dugo ay nagpapababa ng volume, sa mga nagda-dialysis dalawang beses isang linggo, o sa mga bata. Hindi rin ipinakita ng pag-aaral na mas kaunti ang pagka-ospital.Gikan kini sa mga tawo nga stable na sa dialysis sulod sa dili moubos sa tulo ka bulan ug makaabot sa taas nga volume sa HDF. Dili kini mosulti kung unsay mahitabo sa mga tawo nga ang access o presyon sa dugo nagpaubos sa volume, sa mga nagpa-dialysis kaduha sa usa ka semana, o sa mga bata. Wala usab gipakita sa pagtuon nga mas gamay ang pagka-ospital.Ibat la reni karing tau a stable na king dialysis e kukulang atlung bulan at kaya dang abutan ing mataas a volume ning HDF. E na sasabyan nung nanu ing malyari karing tau a ing access o presyun ning daya ra mamababa king volume, karing mag-dialysis makadwa king metung a dominggu, o karing anak. E ne murin pepakit ning pag-aral a mas kakaunti ing pamag-ospital.

Two ways to pull waste across the filterDalawang paraan ng paghila ng dumi sa filterDuha ka paagi sa pagbira sa hugaw sa filterAdwang paralan ning pamanyampid dumi king filter

Your dialyzer is a bundle of thousands of tiny hollow fibers with microscopic pores. Standard HD cleans mainly by diffusion: waste drifts from your blood, where it is crowded, into the clean dialysis fluid, where there is none, much like tea spreading out of a tea bag. Diffusion works very well for small molecules such as urea and potassium, but it is slow for bigger ones.Ang dialyzer mo ay bungkos ng libu-libong maliliit na hollow fiber na may napakaliit na butas. Ang karaniwang HD ay naglilinis pangunahin sa pamamagitan ng diffusion: lumilipat ang dumi mula sa dugo mo, kung saan siksik ito, papunta sa malinis na dialysis fluid, kung saan wala nito, parang tsaang kumakalat mula sa tea bag. Mahusay ang diffusion para sa maliliit na molecule tulad ng urea at potassium, pero mabagal para sa malalaki.Ang imong dialyzer usa ka pungpong sa liboan ka gagmay nga hollow fiber nga adunay gagmay kaayong lungag. Ang naandang HD naglimpyo kasagaran pinaagi sa diffusion: mobalhin ang hugaw gikan sa imong dugo, diin daghan kini, ngadto sa limpyo nga dialysis fluid, diin wala kini, sama sa tsa nga mokaylap gikan sa tea bag. Maayo kaayo ang diffusion alang sa gagmay nga molecule sama sa urea ug potassium, apan hinay alang sa dagko.Ing dialyzer mu bungkus ya ning libu-libung malating hollow fiber a atin malating butas. Ing karaniwan a HD manlinis ya pekamarimla king diffusion: lalako ing dumi ibat king daya mu, nung nu masikip ya, papunta king malinis a dialysis fluid, nung nu ala ya, antimo ing tsa a kakalat ibat king tea bag. Mayap ing diffusion para karing malating molecule antimo ing urea at potassium, oneng malambat ya para karing maragul.

HDF adds convection. The machine pushes a large volume of water from your blood through the fiber walls, and that moving water drags along larger "middle molecules" that diffusion barely touches, the way a river carries sand that would never drift on its own. Because much more water leaves your blood than you need to lose, the machine replaces most of it with sterile, ultra-clean fluid that it makes from the purified dialysis fluid during the session (the "online" part of online HDF).Nagdadagdag ang HDF ng convection. Itinutulak ng makina ang maraming tubig mula sa dugo mo palabas sa dingding ng fiber, at hinihila ng gumagalaw na tubig na ito ang mas malalaking "middle molecule" na halos hindi naaabot ng diffusion, gaya ng ilog na nagdadala ng buhangin na hindi naman kusang lilipat. Dahil mas maraming tubig ang lumalabas sa dugo mo kaysa sa kailangan mong mabawas, pinapalitan ito ng makina ng sterile at napakalinis na fluid na ginagawa nito mula sa purified dialysis fluid habang nagse-session (ito ang "online" sa online HDF).Nagdugang ang HDF og convection. Ituklod sa makina ang daghang tubig gikan sa imong dugo pagawas sa bungbong sa fiber, ug kining naglihok nga tubig magbitad sa mas dagkong "middle molecule" nga halos dili maabot sa diffusion, sama sa suba nga nagdala og balas nga dili man mobalhin sa iyang kaugalingon. Tungod kay mas daghang tubig ang mogawas sa imong dugo kaysa sa kinahanglan nimong makuha, ilisan kini sa makina og sterile ug limpyo kaayo nga fluid nga himoon niini gikan sa purified dialysis fluid samtang nagsession (kini ang "online" sa online HDF).Mamandagdag ing HDF convection. Itulak ning makina ing dakal a danum ibat king daya mu palwal king pader ning fiber, at ing danum a ini a kikilus manyampid ya karing mas maragul a "middle molecule" a e masyadung abutan ning diffusion, antimo ing ilug a magdala balas a e kusang lalako. Uling mas dakal a danum ing lalwal king daya mu kesa king kailangan mung mabawas, salilinan ne ning makina ning sterile at malinis a malinis a fluid a gagawan na ibat king purified dialysis fluid kabang session (iti ing "online" king online HDF).

Side-by-side illustration of a dialyzer fiber: on the left, small waste particles drift across the membrane by diffusion; on the right, water pushed through the membrane drags larger middle molecules with it by convection

Diffusion (left) moves small molecules down a concentration difference. Convection (right) moves water across the membrane under pressure, and the water carries larger middle molecules with it. HDF uses both at once.

HD
Hemodialysis
HDF
Hemodiafiltration
β2M
β2-microglobulin, a marker middle molecule

What "23 liters" means: a worked exampleAng ibig sabihin ng "23 litro": halimbawaAng buot ipasabot sa "23 ka litro": pananglitanIng kayulugan ning "23 a litru": alimbawa

  • Replacement (substitution) fluid given back during the session: 21 LReplacement (substitution) fluid na ibinalik habang session: 21 LReplacement (substitution) fluid nga gibalik samtang session: 21 LReplacement (substitution) fluid a pibalik kabang session: 21 L
  • Extra fluid you actually need to lose (net ultrafiltration): 2 LSobrang tubig na talagang kailangan mong mabawas (net ultrafiltration): 2 LSobrang tubig nga kinahanglan gyud nimong makuha (net ultrafiltration): 2 LSobrang danum a talagang kailangan mung mabawas (net ultrafiltration): 2 L
  • Total water that crossed the filter (convection volume): 21 + 2 = 23 LKabuuang tubig na tumawid sa filter (convection volume): 21 + 2 = 23 LKinatibuk-ang tubig nga mitabok sa filter (convection volume): 21 + 2 = 23 LKabuuan a danum a limipat king filter (convection volume): 21 + 2 = 23 L

You still lose only the 2 L you came in with. The other 21 L were washed through and given back clean. Raising the fluid you lose is never a way to "reach 23."Ang 2 L lang na dala mo ang talagang mababawas sa iyo. Ang ibang 21 L ay dumaan lang at ibinalik nang malinis. Hindi kailanman paraan ang pagdagdag ng tubig na tinatanggal sa iyo para "umabot sa 23."Ang 2 L ra nga imong gidala ang tinuod nga makuha kanimo. Ang laing 21 L miagi lang ug gibalik nga limpyo. Dili gayud paagi ang pagdugang sa tubig nga kuhaon kanimo aron "makaabot sa 23."Ing 2 L mu pamu a dala mu ing talagang mabawas keka. Ing aliwang 21 L miliban mu at pibalik a malinis. E ya kailanman paralan ing pamandagdag ning danum a alisan keka ban "abutan ing 23."

Twenty-three one-liter bottles: twenty-one green bottles of clean fluid returned to the patient and two orange bottles of extra body water removed, with the equation 21 L plus 2 L equals 23 L convection volume

In this example, 23 liters of water pass through the filter in one session, but 21 liters are replaced with clean fluid and returned. Only the 2 liters of extra body water are actually removed.Sa halimbawang ito, 23 litro ng tubig ang dumadaan sa filter sa isang session, pero 21 litro ang pinapalitan ng malinis na fluid at ibinabalik. Ang 2 litro lang na sobrang tubig sa katawan ang talagang tinatanggal.Niini nga pananglitan, 23 ka litro nga tubig ang moagi sa filter sa usa ka session, apan 21 ka litro ang ilisan og limpyo nga fluid ug ibalik. Ang 2 ka litro ra nga sobrang tubig sa lawas ang tinuod nga kuhaon.King alimbawang iti, 23 a litru a danum ing miliban king filter king metung a session, oneng 21 a litru ing salilinan malinis a fluid at ibalik. Ing 2 a litru mu a sobrang danum king katawan ing talagang alisan.

HDF
Hemodiafiltration

There are two set-ups. In post-dilution HDF, the clean fluid is added after the blood leaves the filter; this is the mode tested in the survival trials. In pre-dilution HDF, the fluid is added before the filter, which dilutes the blood first, so its liters are not equal to post-dilution liters and cannot be compared with the 23 L benchmark.May dalawang ayos. Sa post-dilution HDF, idinadagdag ang malinis na fluid pagkatapos lumabas ng dugo sa filter; ito ang paraang sinubok sa mga pag-aaral sa pagkabuhay. Sa pre-dilution HDF, idinadagdag ang fluid bago ang filter, kaya nalalabnaw muna ang dugo; hindi kapantay ng post-dilution ang mga litro nito at hindi maikukumpara sa 23 L na batayan.Adunay duha ka paagi. Sa post-dilution HDF, idugang ang limpyo nga fluid human mogawas ang dugo sa filter; kini ang paagi nga gisulayan sa mga pagtuon sa pagkabuhi. Sa pre-dilution HDF, idugang ang fluid sa wala pa ang filter, busa malabnaw una ang dugo; dili managsama sa post-dilution ang mga litro niini ug dili ikumpara sa 23 L nga sukaranan.Atin adwang ayus. King post-dilution HDF, idagdag ing malinis a fluid kaybat lumwal ing daya king filter; iti ing paralan a sinubuk karing pag-aral king pamagbiye. King pre-dilution HDF, idagdag ing fluid bayu ing filter, anya malabnaw muna ing daya; e la kapareu ning post-dilution ding litru na at e malyaring ikumpara king 23 L a batayan.

Two dialyzers side by side: on the left clean fluid joins the returning blood line after the filter (post-dilution, counts toward 23 liters); on the right clean fluid joins the incoming blood line before the filter (pre-dilution, not comparable to 23 liters)

Post-dilution adds the clean fluid after the filter, the mode used in the survival trials. Pre-dilution adds it before the filter, so its liters are less efficient and cannot be compared with the 23-liter benchmark.Sa post-dilution, idinadagdag ang malinis na fluid pagkatapos ng filter, ang paraang ginamit sa mga pag-aaral sa pagkabuhay. Sa pre-dilution, idinadagdag ito bago ang filter, kaya hindi gaanong episyente ang mga litro nito at hindi maikukumpara sa 23 litro.Sa post-dilution, idugang ang limpyo nga fluid human sa filter, ang paagi nga gigamit sa mga pagtuon sa pagkabuhi. Sa pre-dilution, idugang kini sa wala pa ang filter, busa dili kaayo episyente ang mga litro niini ug dili ikumpara sa 23 ka litro.King post-dilution, idagdag ing malinis a fluid kaybat ning filter, ing paralan a gimit karing pag-aral king pamagbiye. King pre-dilution, idagdag ya bayu ing filter, anya e masyadung episyente ding litru na at e malyaring ikumpara king 23 a litru.

🧪

HDF is not the same as expanded HDHindi pareho ang HDF at expanded HDDili pareho ang HDF ug expanded HDE la pareu ing HDF at expanded HD

Expanded hemodialysis (HDx) uses a special medium cut-off filter on an ordinary HD machine. It also removes more middle molecules, but it works differently and has not been tested for survival the way HDF has. The HDF results cannot be borrowed for HDx. See our HDx guide.Ang expanded hemodialysis (HDx) ay gumagamit ng espesyal na medium cut-off na filter sa karaniwang HD machine. Nagtatanggal din ito ng mas maraming middle molecule, pero iba ang paraan nito at hindi pa nasubok sa pagkabuhay gaya ng HDF. Hindi puwedeng hiramin ang resulta ng HDF para sa HDx. Basahin ang aming gabay sa HDx.Ang expanded hemodialysis (HDx) mogamit og espesyal nga medium cut-off nga filter sa naandang HD machine. Mokuha usab kini og mas daghang middle molecule, apan lahi ang paagi niini ug wala pa masulayi sa pagkabuhi sama sa HDF. Dili mahulam ang resulta sa HDF alang sa HDx. Basaha ang among giya sa HDx.Ing expanded hemodialysis (HDx) gagamit yang espesyal a medium cut-off a filter king karaniwan a HD machine. Mangalis ya murin dakal a middle molecule, oneng aliwa ya paralan at e pa ya asubuk king pamagbiye antimo ing HDF. E malyaring iramin ing resulta ning HDF para king HDx. Basan me ing giya mi king HDx.

What the studies found, in plain languageAng natuklasan ng mga pag-aaral, sa simpleng salitaAng nakaplagan sa mga pagtuon, sa yanong pulongIng akit dareng pag-aral, king simpling amanu

QuestionTanongPangutanaKutangWhat we knowAng alam natinAng nahibal-an natoIng balu tamuHow sureGaano katiyakUnsa ka siguradoMakananu katiyak
Does HDF help people live longer?Nakakatulong ba ang HDF para mabuhay nang mas matagal?Makatabang ba ang HDF aron mabuhi nga mas dugay?Makasaup ya ing HDF ban mabiye la ding tau mas mabayu?Yes, in adults who can receive high volumes. One large trial and pooled analyses of several trials point the same way.Oo, sa mga nasa hustong gulang na kayang tumanggap ng mataas na volume. Isang malaking pag-aaral at pinagsamang pagsusuri ng ilang pag-aaral ang tumuturo sa iisang direksyon.Oo, sa mga hamtong nga makadawat og taas nga volume. Usa ka dakong pagtuon ug hiniusang pagsusi sa pipila ka pagtuon ang nagtudlo sa samang direksyon.Wa, karing matua a kaya dang tumanggap mataas a volume. Metung a maragul a pag-aral at pigsamang pamanyuri dareng aliwang pag-aral ing tuturu king pareung direksyun.ModerateKatamtamanKasaranganKatamtaman
Fewer heart deaths?Mas kaunting pagkamatay dahil sa puso?Mas gamay nga kamatayon tungod sa kasingkasing?Mas kakaunting kematayan uli ning pusu?Probably, when the trials are pooled. The single largest trial could not show it by itself.Malamang, kapag pinagsama ang mga pag-aaral. Hindi ito naipakita ng pinakamalaking pag-aaral nang mag-isa.Lagmit, kung hiusahon ang mga pagtuon. Wala kini mapakita sa kinadak-ang pagtuon nga nag-inusara.Malamang, nung pisamasama ding pag-aral. E ne apakit ning pekamaragul a pag-aral a busbus ya.ModerateKatamtamanKasaranganKatamtaman
Fewer hospital stays?Mas kaunting pagka-ospital?Mas gamay nga pagka-ospital?Mas kakaunting pamag-ospital?Not shown.Hindi naipakita.Wala mapakita.E apakit.LowMababaUbosMababa
Do I feel better?Mas gaganda ba ang pakiramdam ko?Mas maayo ba akong pamati?Mas sasanting ya ing pakiramdam ku?People in both groups slowly felt worse over time, but some areas (physical function, thinking as people rated it, pain, and social life) declined more slowly with HDF. It is not a cure for tiredness.Unti-unting lumala ang pakiramdam ng mga tao sa parehong grupo, pero ang ilang bahagi (pisikal na kakayahan, pag-iisip ayon sa sariling tantiya, sakit, at buhay panlipunan) ay mas mabagal bumaba sa HDF. Hindi ito lunas sa pagod.Hinay-hinay nga misamot ang pamati sa mga tawo sa duha ka grupo, apan ang pipila ka bahin (pisikal nga kapasidad, panghunahuna sumala sa ilang kaugalingong tan-aw, sakit, ug sosyal nga kinabuhi) mas hinay nga mius-os sa HDF. Dili kini tambal sa kakapoy.Dahan-dahang menasama ing pakiramdam dareng tau king adwang grupu, oneng ding aliwang bage (pisikal a kakayanan, pamanisip agpang king sariling tantya, sakit, at bie king aliwang tau) mas malambat a minababa king HDF. E ya lunas king kapagal.LowMababaUbosMababa
Is it safe?Ligtas ba ito?Luwas ba kini?Ligtas ya?Side effects during sessions were similar to HD in trials, in units with strict water-quality systems.Katulad ng HD ang mga side effect habang session sa mga pag-aaral, sa mga unit na may mahigpit na sistema sa kalidad ng tubig.Susama sa HD ang mga side effect samtang session sa mga pagtuon, sa mga unit nga adunay estrikto nga sistema sa kalidad sa tubig.Kapareu ning HD ding side effect kabang session karing pag-aral, karing unit a atin mahigpit a sistema king kalidad ning danum.ModerateKatamtamanKasaranganKatamtaman
Scorecard of five outcomes for high-volume HDF versus high-flux hemodialysis: living longer yes with moderate certainty; fewer heart deaths probably from pooled studies with moderate certainty; fewer hospital stays not shown; slower decline in how people feel in some areas with low certainty; less tiredness not shown

What high-volume HDF changed compared with high-flux HD, and how sure we are. Survival has the strongest evidence; hospital stays and tiredness did not clearly improve.Ang binago ng high-volume HDF kumpara sa high-flux HD, at gaano tayo katiyak. Pinakamalakas ang ebidensiya sa pagkabuhay; hindi malinaw na bumuti ang pagka-ospital at pagod.Ang giusab sa high-volume HDF kumpara sa high-flux HD, ug unsa kita ka sigurado. Pinakalig-on ang ebidensya sa pagkabuhi; wala klaro nga miayo ang pagka-ospital ug kakapoy.Ing mibayu ning high-volume HDF kumpara king high-flux HD, at makananu tamung katiyak. Pekamatibe ing ebidensya king pamagbiye; e malino a meyayu ing pamag-ospital at kapagal.

HD
Hemodialysis
HDF
Hemodiafiltration

Newer evidence from 2026 adds weight. A Cochrane review of 62 studies concluded that convective dialysis, mainly HDF, likely lowers the risk of death. A study of almost 20,000 people treated in routine European dialysis centers also found fewer deaths with sustained high-volume HDF, though a study of that kind cannot fully rule out that healthier people were the ones who received HDF. A large United Kingdom trial (H4RT) has finished recruiting; its results had not been published when this guide was written.Nagdagdag ng bigat ang mas bagong ebidensiya mula 2026. Sinabi ng isang Cochrane review ng 62 pag-aaral na malamang na binabawasan ng convective dialysis, pangunahin ang HDF, ang panganib ng kamatayan. Isang pag-aaral din ng halos 20,000 tao sa karaniwang dialysis center sa Europa ang nakakita ng mas kaunting namatay sa tuloy-tuloy na high-volume HDF, bagaman hindi kayang alisin nang lubos ng ganitong pag-aaral ang posibilidad na mas malulusog na tao ang nabigyan ng HDF. Natapos na ang pagkuha ng kalahok sa isang malaking pag-aaral sa United Kingdom (H4RT); hindi pa nailalathala ang resulta nito nang isulat ang gabay na ito.Nagdugang og gibug-aton ang mas bag-ong ebidensya gikan sa 2026. Miingon ang usa ka Cochrane review sa 62 ka pagtuon nga lagmit makapaubos ang convective dialysis, kasagaran HDF, sa peligro sa kamatayon. Usa usab ka pagtuon sa hapit 20,000 ka tawo sa naandang dialysis center sa Europa ang nakakita og mas gamay nga namatay sa padayon nga high-volume HDF, bisan pa nga dili hingpit makuha sa ingon niini nga pagtuon ang posibilidad nga mas himsog nga mga tawo ang nahatagan og HDF. Nahuman na ang pagkuha og partisipante sa usa ka dakong pagtuon sa United Kingdom (H4RT); wala pa mapatik ang resulta niini sa dihang gisulat kining giya.Mamandagdag bigat ing mas bayung ebidensya ibat king 2026. Sinabi ning metung a Cochrane review ning 62 a pag-aral a malamang mamababa ing convective dialysis, pekamarimla ing HDF, king panganib ning kematayan. Metung murin a pag-aral ning malapit 20,000 a tau karing karaniwan a dialysis center king Europa ing akit dang mas kakaunting mete king tuloy-tuloy a high-volume HDF, maliban king e kayang alisan a lubus ning anti kaniting pag-aral ing posibilidad a mas masalusu a tau ing mebyan HDF. Mebusni ing pamakua kalahuk king metung a maragul a pag-aral king United Kingdom (H4RT); e pa milalwal ing resulta na kanita sinulat ing giya a ini.

Who the evidence fits, and where it is thinKanino tugma ang ebidensiya, at saan ito kulangKang kinsa haom ang ebidensya, ug asa kini kulangNanu ing tugma ning ebidensya, at nokarin ya kulang

The evidence fits best if you are an adult on in-center hemodialysis three times a week, your fistula, graft, or catheter gives steady blood flow, you tolerate your sessions, and you want HDF. No single feature, such as age, diabetes, heart disease, or having a catheter, automatically rules you in or out. What matters is whether you can actually receive a high volume session after session.Pinakaangkop ang ebidensiya kung ikaw ay nasa hustong gulang na nagda-dialysis sa center tatlong beses isang linggo, ang fistula, graft, o catheter mo ay nagbibigay ng tuloy-tuloy na daloy ng dugo, kaya mo ang iyong mga session, at gusto mo ang HDF. Walang iisang katangian, tulad ng edad, diabetes, sakit sa puso, o pagkakaroon ng catheter, na awtomatikong nagsasama o nag-aalis sa iyo. Ang mahalaga ay kung talagang makakatanggap ka ng mataas na volume session pagkatapos ng session.Labing haom ang ebidensya kung ikaw hamtong nga nagpa-dialysis sa center tulo ka beses sa usa ka semana, ang imong fistula, graft, o catheter naghatag og padayon nga agos sa dugo, makaya nimo ang imong mga session, ug gusto nimo ang HDF. Walay usa ka kinaiya, sama sa edad, diabetes, sakit sa kasingkasing, o adunay catheter, nga awtomatikong maglakip o magpagawas kanimo. Ang importante mao kung makadawat ba gyud ka og taas nga volume matag session.Pekaangkup ing ebidensya nung matua ka a mag-dialysis king center makatlu king metung a dominggu, ing fistula, graft, o catheter mu mibie yang tuloy-tuloy a agus ning daya, kaya mu ding session mu, at buri mu ing HDF. Ala yang metung a katangian, antimo ing idad, diabetes, sakit king pusu, o atin catheter, a awtomatikung mamasok o mangalis keka. Ing mayalaga, nung talagang makatanggap ka mataas a volume balang session.

Two panels: well studied, showing an adult on in-center dialysis three times a week with steady access; and less known, with six tiles for twice-weekly dialysis, first weeks of dialysis, children, home dialysis, very frail people, and volume that often stays low

The survival evidence comes mainly from adults on in-center dialysis three times a week who could receive a high volume. For other situations the evidence is thin, and the decision rests on your team and your goals.Ang ebidensiya sa pagkabuhay ay galing pangunahin sa mga nasa hustong gulang na nagda-dialysis sa center tatlong beses isang linggo na kayang tumanggap ng mataas na volume. Sa ibang sitwasyon, kulang ang ebidensiya, at nakasalalay ang desisyon sa iyong team at sa iyong mga layunin.Ang ebidensya sa pagkabuhi gikan kasagaran sa mga hamtong nga nagpa-dialysis sa center tulo ka beses sa usa ka semana nga makadawat og taas nga volume. Sa ubang sitwasyon, kulang ang ebidensya, ug nagdepende ang desisyon sa imong team ug sa imong mga tumong.Ing ebidensya king pamagbiye ibat ya pekamarimla karing matua a mag-dialysis king center makatlu king metung a dominggu a kaya dang tumanggap mataas a volume. King aliwang sitwasyun, kulang ing ebidensya, at makasalalay ing desisyun king team mu at karing layunin mu.

HDF
Hemodiafiltration
⚠️

Where we have little or no evidenceKung saan kaunti o walang ebidensiyaDiin gamay o walay ebidensyaNung nu kakaunti o ala yang ebidensya

Dialysis twice a week or incremental dialysis; the first weeks after starting dialysis; children; home HD; very frail people; and people whose access or blood pressure keeps volumes low. In these situations the decision rests on your team's judgment and your goals, not on the trial numbers.Dialysis dalawang beses isang linggo o incremental dialysis; ang mga unang linggo matapos magsimula ng dialysis; mga bata; home HD; napakahinang mga tao; at mga taong ang access o presyon ng dugo ay nagpapababa ng volume. Sa mga sitwasyong ito, nakasalalay ang desisyon sa paghuhusga ng iyong team at sa iyong mga layunin, hindi sa numero ng pag-aaral.Dialysis kaduha sa usa ka semana o incremental dialysis; ang unang mga semana human magsugod og dialysis; mga bata; home HD; luya kaayo nga mga tawo; ug mga tawo nga ang access o presyon sa dugo nagpaubos sa volume. Niining mga sitwasyon, nagdepende ang desisyon sa paghukom sa imong team ug sa imong mga tumong, dili sa numero sa pagtuon.Dialysis makadwa king metung a dominggu o incremental dialysis; ding mumunang dominggu kaybat mumpisa dialysis; reng anak; home HD; makapaluyang tau; at reng tau a ing access o presyun ning daya ra mamababa king volume. Karing sitwasyun a reni, makasalalay ing desisyun king pamanimbang ning team mu at karing layunin mu, e karing numeru ning pag-aral.

Four questions, in orderApat na tanong, sunod-sunodUpat ka pangutana, sunod-sunodApat a kutang, sunud-sunud

Deciding together with your teamPagpapasya kasama ang iyong teamPagdesisyon uban sa imong teamPamagpasya kayabe ing team mu
1
Is this right for my situation, and do I want it?Angkop ba ito sa sitwasyon ko, at gusto ko ba ito?Haom ba kini sa akong sitwasyon, ug gusto ba nako kini?Angkup ya king sitwasyun ku, at buri ku ya? You dialyze in a center three times a week and you are interested after hearing the benefits, the unknowns, and the costs.Nagda-dialysis ka sa center tatlong beses isang linggo at interesado ka matapos marinig ang mga benepisyo, ang hindi pa alam, at ang gastos.Nagpa-dialysis ka sa center tulo ka beses sa usa ka semana ug interesado ka human madungog ang mga kaayohan, ang wala pa mahibal-i, ug ang gasto.Mag-dialysis ka king center makatlu king metung a dominggu at interesadu ka kaybat mung arinig ing benepisyu, ing e pa balu, at ing gastus.
2
Is my unit ready?Handa ba ang aking unit?Andam ba ang akong unit?Handa ya ing unit ku? The unit has HDF-capable machines, trained staff, a water system that makes ultra-clean fluid with regular testing, and a backup plan.May HDF-capable na makina ang unit, sanay na staff, sistema ng tubig na gumagawa ng napakalinis na fluid na regular na sinusuri, at backup na plano.Adunay HDF-capable nga makina ang unit, batid nga staff, sistema sa tubig nga mohimo og limpyo kaayo nga fluid nga regular nga gisusi, ug backup nga plano.Atin HDF-capable a makina ing unit, sanay a staff, sistema ning danum a gagawa malinis a malinis a fluid a regular dang susurian, at backup a planu.
3
Can my access and my body handle it, session after session?Kaya ba ng aking access at katawan, session pagkatapos ng session?Makaya ba sa akong access ug lawas, matag session?Kaya na ning access ku at katawan ku, balang session? Your access gives good blood flow, sessions are long enough, and your blood pressure stays steady. If not, the team works on the cause first.Maganda ang daloy ng dugo sa access mo, sapat ang haba ng session, at stable ang presyon ng dugo mo. Kung hindi, aayusin muna ng team ang sanhi.Maayo ang agos sa dugo sa imong access, igo ang gitas-on sa session, ug stable ang imong presyon sa dugo. Kung dili, ayohon una sa team ang hinungdan.Mayap ing agus ning daya king access mu, sapat ing kabayan ning session, at stable ing presyun ning daya mu. Nung ali, ayusan muna ning team ing sanhi.
4
Is the cost acceptable to me?Katanggap-tanggap ba sa akin ang gastos?Madawat ba nako ang gasto?Katanggap-tanggap ya keku ing gastus? You have a written quote per session and know how many sessions a month it adds up to, including transport.May nakasulat kang quote bawat session at alam mo kung magkano ito sa isang buwan, kasama ang pamasahe.Aduna kay sinulat nga quote matag session ug nahibal-an nimo kung pila kini sa usa ka bulan, lakip ang plete.Atin kang nakasulat a quote balang session at balu mu nung magkanu ya king metung a bulan, kayabe ing pamasahe.
✅

If any answer is still "not yet"Kung "hindi pa" ang alinmang sagotKung "dili pa" ang bisan unsang tubagNung "e pa" ing nanumang sagot

Keep going with good high-flux HD while the team fixes the limiting factor. You are not getting "second-class" treatment by waiting. Switching to HDF that cannot reach a high volume is not the HDF that was proven in the trial.Ituloy ang maayos na high-flux HD habang inaayos ng team ang hadlang. Hindi ka binibigyan ng "pangalawang klase" na gamutan habang naghihintay. Ang paglipat sa HDF na hindi umaabot sa mataas na volume ay hindi ang HDF na napatunayan sa pag-aaral.Padayon sa maayong high-flux HD samtang ayohon sa team ang babag. Wala ka gihatagi og "ikaduhang klase" nga pagtambal samtang naghulat. Ang pagbalhin sa HDF nga dili makaabot sa taas nga volume dili mao ang HDF nga napamatud-an sa pagtuon.Ituloy ing mayap a high-flux HD kabang ayusan ning team ing aharang. E ka bibyan "ikaduang klasi" a panulu kabang maintai ka. Ing pamanlipat king HDF a e abutan ing mataas a volume, e ya ing HDF a apatunayan king pag-aral.

A four-step pathway for deciding on hemodiafiltration: interest and fit, unit readiness, access and tolerance, and cost, with a side path to continue high-flux hemodialysis while any step is resolved

The four decisions in order. Any unresolved step leads to continued high-flux hemodialysis while the team works on that step, not to a lower-quality HDF.

HD
Hemodialysis
HDF
Hemodiafiltration

What PhilHealth covers and what you may payAng sakop ng PhilHealth at ang maaaring bayaran moAng sakop sa PhilHealth ug ang mahimong bayran nimoIng sakup ning PhilHealth at ing malyaring bayaran mu

Under Circular 2024-0023 of the Philippine Health Insurance Corporation (PhilHealth), PhilHealth pays up to ₱6,350 per hemodialysis session for up to 156 sessions a calendar year for eligible members and dependents with chronic kidney disease stage 5, at accredited facilities. Items inside the package should carry no extra charge. PhilHealth lists hemodiafiltration among the premium services outside the package, so a unit may charge you extra for it.Sa ilalim ng PhilHealth Circular 2024-0023, nagbabayad ang PhilHealth ng hanggang ₱6,350 bawat session ng hemodialysis para sa hanggang 156 session bawat taon para sa mga kwalipikadong miyembro at dependent na may chronic kidney disease stage 5, sa mga accredited na pasilidad. Walang dagdag na singil dapat ang mga kasama sa package. Inililista ng PhilHealth ang hemodiafiltration bilang isa sa mga premium service na labas sa package, kaya puwede kang singilin ng dagdag ng unit para dito.Ubos sa PhilHealth Circular 2024-0023, mobayad ang PhilHealth og hangtod ₱6,350 matag session sa hemodialysis alang sa hangtod 156 ka session matag tuig alang sa mga kwalipikado nga miyembro ug dependent nga adunay chronic kidney disease stage 5, sa mga accredited nga pasilidad. Walay dugang bayad angay ang mga sulod sa package. Gilista sa PhilHealth ang hemodiafiltration isip usa sa mga premium service nga gawas sa package, busa mahimong pabayran ka og dugang sa unit alang niini.King lalam ning PhilHealth Circular 2024-0023, mamayad ya ing PhilHealth anggang ₱6,350 balang session ning hemodialysis para anggang 156 a session balang taun para karing kwalipikadung miembru at dependent a atin chronic kidney disease stage 5, karing accredited a pasilidad. Ala dapat dagdag a bayad ding kayabe king package. Ilista ning PhilHealth ing hemodiafiltration kayabe dareng premium service a ali kayabe king package, anya malyari kang pabayaran dagdag ning unit para kaniti.

Stacked block for one session: a large teal block for the PhilHealth hemodialysis benefit of up to 6,350 pesos per session and up to 156 sessions a year, topped by a smaller dashed amber block for a possible facility-specific HDF premium, beside a reminder to ask for any extra charge, the monthly total and travel cost in writing

PhilHealth pays up to ₱6,350 per hemodialysis session for up to 156 sessions a year. HDF is listed as a premium service, so any extra charge is separate and must be disclosed in writing.Nagbabayad ang PhilHealth ng hanggang ₱6,350 bawat session ng hemodialysis para sa hanggang 156 session bawat taon. Nakalista ang HDF bilang premium service, kaya hiwalay ang anumang dagdag na singil at dapat nakasulat.Mobayad ang PhilHealth og hangtod ₱6,350 matag session sa hemodialysis alang sa hangtod 156 ka session matag tuig. Nakalista ang HDF isip premium service, busa lahi ang bisan unsang dugang bayad ug kinahanglan nga sinulat.Mamayad ya ing PhilHealth anggang ₱6,350 balang session ning hemodialysis para anggang 156 a session balang taun. Nakalista ya ing HDF bilang premium service, anya iwalay ing nanumang dagdag a bayad at dapat nakasulat.

HDF
Hemodiafiltration
PhilHealth
Philippine Health Insurance Corporation
Before you agree to HDF, ask forBago ka pumayag sa HDF, hingin angSa dili pa ka mouyon sa HDF, pangayoa angBayu ka sumang-ayun king HDF, pakisabi ing
1
A written breakdown of any extra charge per session, separate from what PhilHealth pays. Co-payments must be explained to you and recorded on the PhilHealth agreement form for each session.Isang nakasulat na breakdown ng anumang dagdag na singil bawat session, hiwalay sa binabayaran ng PhilHealth. Dapat ipaliwanag sa iyo ang co-payment at itala sa PhilHealth agreement form bawat session.Usa ka sinulat nga breakdown sa bisan unsang dugang bayad matag session, lahi sa gibayran sa PhilHealth. Kinahanglan ipasabot kanimo ang co-payment ug irekord sa PhilHealth agreement form matag session.Metung a nakasulat a breakdown ning nanumang dagdag a bayad balang session, iwalay king babayaran ning PhilHealth. Dapat ipaliwanag keka ing co-payment at isulat king PhilHealth agreement form balang session.
2
The monthly total: 3 sessions a week is about 13 sessions a month.Ang kabuuan sa isang buwan: ang 3 session isang linggo ay mga 13 session sa isang buwan.Ang kinatibuk-an sa usa ka bulan: ang 3 ka session sa usa ka semana mga 13 ka session sa usa ka bulan.Ing kabuuan king metung a bulan: ing 3 a session king metung a dominggu malapit 13 a session king metung a bulan.
3
Whether HDF means a different schedule or branch, and the extra transport cost.Kung ang HDF ay nangangahulugan ng ibang schedule o branch, at ang dagdag na pamasahe.Kung ang HDF nagpasabot og laing schedule o branch, ug ang dugang plete.Nung ing HDF kayulugan na aliwang schedule o branch, at ing dagdag a pamasahe.
4
What happens to the charge if your HDF session has to be done as HD that day.Ano ang mangyayari sa singil kung kailangang gawing HD ang HDF session mo sa araw na iyon.Unsay mahitabo sa bayad kung kinahanglan himoong HD ang imong HDF session nianang adlawa.Nanu ing malyari king bayad nung kailangan dang gawan HD ing HDF session mu king aldo a ita.

No fixed HDF surcharge exists across the Philippines; prices differ by facility and change over time. Use the patient cost tool in our HDx & Convection Toolkit to total a quote you have been given. Example: a ₱500 premium plus ₱100 extra transport per session, for 12 sessions, comes to ₱7,200.Walang nakapirming dagdag na singil sa HDF sa buong Pilipinas; iba-iba ang presyo sa bawat pasilidad at nagbabago sa paglipas ng panahon. Gamitin ang patient cost tool sa aming HDx & Convection Toolkit para kuwentahin ang quote na ibinigay sa iyo. Halimbawa: ₱500 na premium at ₱100 na dagdag na pamasahe bawat session, sa 12 session, ay ₱7,200.Walay piho nga dugang bayad sa HDF sa tibuok Pilipinas; lain-lain ang presyo sa matag pasilidad ug mausab sa paglabay sa panahon. Gamita ang patient cost tool sa among HDx & Convection Toolkit aron kuwentahon ang quote nga gihatag kanimo. Pananglitan: ₱500 nga premium ug ₱100 nga dugang plete matag session, sa 12 ka session, mokabat og ₱7,200.Ala yang pirming dagdag a bayad king HDF king sablang Pilipinas; aliwa-aliwa ing presyu king balang pasilidad at magbayu ya king panaun. Gamitan me ing patient cost tool king HDx & Convection Toolkit mi ban kuwentan ing quote a mibie keka. Alimbawa: ₱500 a premium at ₱100 a dagdag a pamasahe balang session, king 12 a session, ₱7,200 ya.

Questions to ask your dialysis teamMga tanong para sa iyong dialysis teamMga pangutana alang sa imong dialysis teamReng kutang para king dialysis team mu

1
"Am I likely to tolerate and receive high-volume HDF regularly?""Malamang ba na kakayanin ko at regular na makakatanggap ng high-volume HDF?""Lagmit ba nga makaya nako ug regular nga makadawat og high-volume HDF?""Malamang ya a kayanan ku at regular kung makatanggap high-volume HDF?"
2
"What volume was actually delivered in my last sessions?""Gaano kalaking volume ang talagang naibigay sa mga huling session ko?""Pila ka dako nga volume ang tinuod nga nahatag sa akong katapusang mga session?""Makananu karagul a volume ing talagang mebye karing pekamuling session ku?"
3
"What will I pay per session, and per month?""Magkano ang babayaran ko bawat session, at bawat buwan?""Pila ang akong bayran matag session, ug matag bulan?""Magkanu ing bayaran ku balang session, at balang bulan?"
4
"What happens if the target is missed again and again?""Ano ang mangyayari kung paulit-ulit na hindi naaabot ang target?""Unsay mahitabo kung balik-balik nga dili maabot ang target?""Nanu ing malyari nung paulit-ulit a e abutan ing target?"
5
"How will we know if my symptoms or recovery after sessions change?""Paano natin malalaman kung nagbago ang mga sintomas ko o ang paggaling ko pagkatapos ng session?""Unsaon nato pagkahibalo kung nausab ang akong mga sintomas o ang akong pagkaayo human sa session?""Makananu tang abalu nung mibayu ding sintomas ku o ing pamag-ayus ku kaybat ning session?"
Printable card titled Before switching to HDF, ask your team, listing five questions with check boxes and a space for notes

Five questions to bring to your dialysis team. You can save or print this card.Limang tanong na dadalhin sa iyong dialysis team. Puwede mong i-save o i-print ang card na ito.Lima ka pangutana nga dad-on sa imong dialysis team. Mahimo nimong i-save o i-print kining card.Limang kutang a dalan mu king dialysis team mu. Malyari mung i-save o i-print ing card a iti.

HDF
Hemodiafiltration

Common questionsMga karaniwang tanongKasagarang pangutanaReng karaniwan a kutang

Will HDF make me feel less tired after dialysis?Mababawasan ba ng HDF ang pagod ko pagkatapos ng dialysis?Makapamenos ba ang HDF sa akong kakapoy human sa dialysis?Mabawasan na ning HDF ing kapagal ku kaybat ning dialysis?
Not reliably. Trials did not show clear relief of fatigue. Tiredness after dialysis has many causes, including fluid removal speed, anemia, sleep, and mood, and these deserve their own attention. See our post-dialysis fatigue guide.Hindi tiyak. Hindi malinaw na ipinakita ng mga pag-aaral na nababawasan ang pagod. Maraming sanhi ang pagod pagkatapos ng dialysis, kasama ang bilis ng pagtanggal ng tubig, anemia, tulog, at mood, at dapat tingnan ang bawat isa. Basahin ang aming gabay sa pagod pagkatapos ng dialysis.Dili sigurado. Wala klarong gipakita sa mga pagtuon nga mamenosan ang kakapoy. Daghang hinungdan ang kakapoy human sa dialysis, lakip ang kapaspas sa pagkuha og tubig, anemia, katulog, ug mood, ug angay tan-awon ang matag usa. Basaha ang among giya sa kakapoy human sa dialysis.E tiyak. E malino a pepakit dareng pag-aral a mabawasan ing kapagal. Dakal a sanhi ing kapagal kaybat ning dialysis, kayabe ing kasikan ning pangalis danum, anemia, tudtud, at mood, at dapat lawan ing balang metung. Basan me ing giya mi king kapagal kaybat ning dialysis.
Is the replacement fluid safe to put into my blood?Ligtas bang ipasok sa dugo ko ang replacement fluid?Luwas ba nga isulod sa akong dugo ang replacement fluid?Ligtas yang ipasok king daya ku ing replacement fluid?
It is safe only when the unit's water treatment, filters, disinfection, and testing meet strict standards for sterile, non-pyrogenic (fever-free) fluid. That is why unit readiness is step two. It is fair to ask how your unit checks its water.Ligtas lamang ito kapag ang water treatment, filter, disinfection, at pagsusuri ng unit ay pumapasa sa mahigpit na pamantayan para sa sterile at non-pyrogenic (hindi nagdudulot ng lagnat) na fluid. Kaya ang kahandaan ng unit ang ikalawang hakbang. Makatwirang itanong kung paano sinusuri ng unit ang tubig nito.Luwas lamang kini kung ang water treatment, filter, disinfection, ug pagsusi sa unit nakaabot sa estrikto nga sukaranan alang sa sterile ug non-pyrogenic (dili hinungdan og hilanat) nga fluid. Mao nga ang kaandam sa unit ang ikaduhang lakang. Makatarunganon ang pagpangutana kung unsaon pagsusi sa unit ang iyang tubig.Ligtas ya mu nung ing water treatment, filter, disinfection, at pamanyuri ning unit pasa la king mahigpit a pamantayan para king sterile at non-pyrogenic (e mamye lagnat) a fluid. Anya ing kahandaan ning unit ing ikaduang lakad. Makatwiran ing kutnan nung makananu nang susurian ning unit ing danum na.
My unit offers HDF but only reaches about 15 to 18 liters. Is that the same?Nag-aalok ng HDF ang unit ko pero mga 15 hanggang 18 litro lang ang naaabot. Pareho ba iyon?Nagtanyag og HDF ang akong unit apan mga 15 hangtod 18 ka litro ra ang maabot. Pareho ba kana?Mag-alok yang HDF ing unit ku oneng malapit 15 anggang 18 a litru mu ing aabutan. Pareu ya?
Not quite. Lower-volume HDF trials did not show the same survival benefit. Ask whether blood flow, session time, or access can be improved, and whether that volume is post-dilution or pre-dilution.Hindi eksakto. Hindi nagpakita ng parehong benepisyo sa pagkabuhay ang mga pag-aaral ng mas mababang volume na HDF. Itanong kung mapapabuti ang daloy ng dugo, haba ng session, o access, at kung post-dilution o pre-dilution ang volume na iyon.Dili eksakto. Wala nagpakita og samang kaayohan sa pagkabuhi ang mga pagtuon sa mas ubos nga volume nga HDF. Pangutan-a kung mapaayo ba ang agos sa dugo, gitas-on sa session, o access, ug kung post-dilution o pre-dilution ang maong volume.E eksaktu. E la pepakit pareung benepisyu king pamagbiye ding pag-aral ning mas mababang volume a HDF. Kutnan me nung mapasanting ing agus ning daya, kabayan ning session, o access, at nung post-dilution o pre-dilution ing volume a ita.
If I stay on high-flux HD, am I missing out?Kung mananatili ako sa high-flux HD, may nawawala ba sa akin?Kung magpabilin ko sa high-flux HD, aduna bay mawala kanako?Nung manatili ku king high-flux HD, atin yang mawala keku?
High-flux HD remains standard, effective treatment. Getting your dialysis hours, dry weight, potassium, phosphate, anemia, and blood pressure right matters a great deal whichever method you use.Nananatiling pamantayan at mabisang gamutan ang high-flux HD. Napakahalaga ang tamang oras ng dialysis, dry weight, potassium, phosphate, anemia, at presyon ng dugo anuman ang paraang gamit mo.Nagpabilin nga sukaranan ug epektibo nga pagtambal ang high-flux HD. Importante kaayo ang husto nga oras sa dialysis, dry weight, potassium, phosphate, anemia, ug presyon sa dugo bisan unsang paagi ang imong gamiton.Manatili yang pamantayan at mabisang panulu ing high-flux HD. Mayalaga ing tamang oras ning dialysis, dry weight, potassium, phosphate, anemia, at presyun ning daya nanuman ing paralan a gamitan mu.
Can HDF be done twice a week?Puwede bang gawin ang HDF dalawang beses isang linggo?Mahimo ba ang HDF kaduha sa usa ka semana?Malyari yang gawan ing HDF makadwa king metung a dominggu?
It can be done, but the survival trials studied three sessions a week. We do not know whether the benefit carries over to twice-weekly or incremental schedules. See our incremental dialysis guide.Puwede, pero tatlong session isang linggo ang pinag-aralan sa mga pag-aaral sa pagkabuhay. Hindi natin alam kung pareho ang benepisyo sa dalawang beses isang linggo o incremental na schedule. Basahin ang aming gabay sa incremental dialysis.Mahimo, apan tulo ka session sa usa ka semana ang gitun-an sa mga pagtuon sa pagkabuhi. Wala nato mahibal-i kung pareho ang kaayohan sa kaduha sa usa ka semana o incremental nga schedule. Basaha ang among giya sa incremental dialysis.Malyari, oneng atlung session king metung a dominggu ing pig-aralan karing pag-aral king pamagbiye. E tamu balu nung pareu ing benepisyu king makadwa king metung a dominggu o incremental a schedule. Basan me ing giya mi king incremental dialysis.

The short answer for clinicians

High-volume post-dilution online hemodiafiltration (HDF) is a reasonable preferred option for adults on thrice-weekly maintenance in-center hemodialysis (HD) when the unit can deliver it safely and consistently and the patient wants it. High-flux HD remains appropriate standard care when HDF is unavailable, unsuitable, burdensome or cannot be delivered reliably. The best direct survival evidence comes from adults selected for their ability to receive a convection volume of at least 23 L per session, so "the new standard" holds for that population and that dose, not for HDF as a label.

Mortality

CONVINCE: hazard ratio (HR) 0.77 (95% confidence interval [CI] 0.65–0.93) for all-cause death; individual participant data (IPD) meta-analysis HR 0.84 (0.74–0.95); Cochrane 2026 risk ratio (RR) 0.88 (0.80–0.96), moderate certainty.

Not shown

Fewer hospitalizations; fewer nonfatal cardiovascular (CV) events; relief of fatigue; benefit at low convection volume, with pre-dilution, twice-weekly or incremental schedules, or in children.

Decision hinges on

Unit readiness (ultrapure fluid, validated online substitution, staff), deliverable dose (access, blood flow, time, tolerance), patient preference and out-of-pocket cost in the Philippines.

Why convection reaches what diffusion misses

Diffusion moves solute down its concentration gradient at a rate that falls steeply with molecular size, because the diffusive coefficient scales roughly inversely with molecular radius. Urea (60 Da) and potassium are cleared efficiently; β2-microglobulin (β2M, about 11.8 kDa), free light chains, complement factor D and many cytokines are cleared poorly even across high-flux membranes. Convection moves plasma water across the membrane under a transmembrane pressure (TMP) gradient, and solutes small enough to pass the pores are carried with that water at a rate set by the ultrafiltration flux and each solute's sieving coefficient, largely independent of size up to the membrane cut-off. Convective clearance therefore scales with the volume of water filtered, which is why HDF behaves as a dose-dependent therapy.

Because the filtered volume far exceeds the fluid the patient needs to lose, sterile, nonpyrogenic substitution fluid is reinfused. In post-dilution HDF it enters downstream of the dialyzer, so the filter sees undiluted blood and each liter filtered carries the full plasma solute concentration; the limit is hemoconcentration inside the fiber, which rises with filtration fraction and raises TMP, protein layering and clotting risk. In pre-dilution HDF, fluid enters upstream, diluting blood before the membrane; much larger volumes are possible but each liter is less efficient, so pre-dilution liters are not interchangeable with post-dilution liters and should never be read against the 23 L benchmark. Convection volume is defined as substitution volume + net ultrafiltration (Tattersall & Ward, 2013).

Worked example: substitution versus net removal

  • Substitution volume delivered: 21 L
  • Net ultrafiltration (patient fluid removal): 2 L
  • Convection volume = 21 + 2 = 23 L; the patient loses 2 L net.
  • Over 240 minutes, total filtration of 23 L requires about 96 mL/min, which is about 27% of a 350 mL/min blood flow (arithmetic illustration only; achievable filtration depends on hematocrit, total protein, membrane, device limits and local protocol).

The practical levers are therefore blood flow, effective treatment time and the achievable filtration fraction. Raising net ultrafiltration to "hit 23 L" is a prescribing error: it converts a solute-clearance target into a volume-removal and hypotension risk.

Post-dilution online hemodiafiltration circuit: arterial line, blood pump, dialyzer with countercurrent dialysate, online substitution fluid produced from ultrapure dialysate through two ultrafilters and reinfused downstream of the dialyzer, with a 21 L substitution plus 2 L net ultrafiltration equals 23 L annotation

Post-dilution online HDF. Ultrapure dialysis fluid passes through additional ultrafilters to make sterile, nonpyrogenic substitution fluid, which is reinfused after the dialyzer. Convection volume is substitution plus net ultrafiltration.

HDF
Hemodiafiltration
UF
Ultrafiltration
TMP
Transmembrane pressure
Qb
Blood flow rate
Two dialyzers side by side: on the left clean fluid joins the returning blood line after the filter (post-dilution, counts toward 23 liters); on the right clean fluid joins the incoming blood line before the filter (pre-dilution, not comparable to 23 liters)

Post-dilution adds the clean fluid after the filter, the mode used in the survival trials. Pre-dilution adds it before the filter, so its liters are less efficient and cannot be compared with the 23-liter benchmark.Sa post-dilution, idinadagdag ang malinis na fluid pagkatapos ng filter, ang paraang ginamit sa mga pag-aaral sa pagkabuhay. Sa pre-dilution, idinadagdag ito bago ang filter, kaya hindi gaanong episyente ang mga litro nito at hindi maikukumpara sa 23 litro.Sa post-dilution, idugang ang limpyo nga fluid human sa filter, ang paagi nga gigamit sa mga pagtuon sa pagkabuhi. Sa pre-dilution, idugang kini sa wala pa ang filter, busa dili kaayo episyente ang mga litro niini ug dili ikumpara sa 23 ka litro.King post-dilution, idagdag ing malinis a fluid kaybat ning filter, ing paralan a gimit karing pag-aral king pamagbiye. King pre-dilution, idagdag ya bayu ing filter, anya e masyadung episyente ding litru na at e malyaring ikumpara king 23 a litru.

Why might more convection lower mortality?

The mechanism of the survival effect is not established, and the evidence ladder matters here. Established physiology: HDF lowers predialysis β2M and other middle-molecule concentrations. Mechanistic hypotheses: less chronic inflammation and endothelial injury from retained middle molecules, better hemodynamic stability from convective heat loss and sodium kinetics, and the ultrapure fluid that HDF requires. In CONVINCE the mortality difference was not driven by CV death and an infection-related signal appeared, a pattern that does not fit a simple "middle molecules cause atherosclerosis" story. Treat any mechanism as plausible but unproven, and anchor the recommendation on the outcome data, not on biomarker change.

Mechanism schematic: a dialysis patient with a forearm fistula and dialyzer, a magnified vessel-and-fiber inset where middle molecules leave by convection, certainty tags marking lower middle-molecule levels as established and reduced inflammation, steadier blood pressure and lower endotoxin exposure as hypotheses, and a bottom flow ending in lower all-cause mortality with the mechanism not established

HDF reliably lowers middle-molecule levels; why it lowered mortality is not established, and the leading explanations remain hypotheses. CONVINCE alone did not show a reduction in cardiovascular deaths.

HDF
Hemodiafiltration
β2M
β2-microglobulin

How HDF differs from expanded HD

Expanded hemodialysis (HDx) uses a medium cut-off (MCO) membrane whose larger pores and internal filtration–backfiltration enhance middle-molecule removal on a standard HD machine without online substitution fluid. It is a different membrane strategy with different albumin handling and no hard-outcome trial; the HDF mortality evidence cannot be assigned to it. See Expanded Hemodialysis (HDx).

The evidence, appraised

CONVINCE, the pivotal trial

CONVINCE was a pragmatic, multinational, open-label trial of 1,360 adults on high-flux HD for at least 3 months who were judged able to achieve a convection volume of at least 23 L per session and to complete patient-reported outcome assessments (Blankestijn et al., 2023). High-dose post-dilution HDF (n = 683) was compared with continued high-flux HD (n = 677). Mean delivered convection volume was 25.3 L per session, and the target was reached in about 92% of delivered HDF sessions. Over a median 30 months (interquartile range 27–38), death from any cause occurred in 118 of 683 (17.3%) versus 148 of 677 (21.9%), HR 0.77 (0.65–0.93).

CONVINCE endpointHDF vs high-flux HDReading
All-cause death (primary)HR 0.77 (0.65–0.93); 118/683 vs 148/677Crude difference 4.6 percentage points over trial follow-up; crude number needed to treat (NNT) about 22 over roughly 30 months
CV deathHR 0.81 (0.49–1.33)Inconclusive alone
Fatal or nonfatal CV eventsHR 1.07 (0.86–1.33)No difference shown
Infection-related death, including coronavirus disease 2019 (COVID-19)HR 0.69 (0.49–0.96)Secondary signal; the estimate excluding COVID-19 deaths (0.68, 0.42–1.10) is imprecise
Recurrent all-cause hospitalizationHR 1.11 (0.98–1.25)No benefit shown

The crude proportions come from variable follow-up and are shown for scale; the HR is the time-to-event comparison. Secondary-outcome estimates are from the trial's endpoint table; verify against the primary publication before quoting in decision aids.

Appraisal. Randomization was robust and the primary endpoint is hard. Limits: open label; a selected, relatively healthy population (eligibility required capacity for high convection and questionnaire completion); European care settings; follow-up overlapping the COVID-19 pandemic; and a mortality effect without a matching CV or hospitalization effect. Funding was public (European Commission Horizon 2020); industry partners collaborated, and several investigators have device-manufacturer affiliations.

Earlier randomized trials

TrialPopulation and comparatorAll-cause deathInterpretation
ESHOL (Maduell et al., 2013)906 adults; post-dilution online HDF vs continued HD (mostly high-flux)HR 0.70 (0.53–0.92)Supportive; infection-related death HR 0.45 (0.21–0.96). Post-randomization discontinuation and access-related selection complicate interpretation
CONTRAST (Grooteman et al., 2012)714 adults; post-dilution HDF vs low-flux HD; mean 3.0 yearsHR 0.95 (0.75–1.20)Neutral; higher achieved-volume associations are on-treatment and exploratory
Turkish online HDF trial (Ok et al., 2013)782 adults; post-dilution HDF vs high-flux HD; mean substitution about 17 LComposite event-free survival 77.6% vs 74.8% (P = .28)Neutral at a low delivered volume; post hoc >17.4 L substitution subgroup is hypothesis-generating, not a causal cut-off
FRENCHIE (Morena et al., 2017)381 adults over 65; online HDF vs high-flux HD; tolerance endpointNot poweredAt least one intradialytic adverse event in 84% vs 85% of patients; fewer hypotension and cramp episodes at the session level (exploratory)

Syntheses (overlapping, not independent)

The IPD meta-analysis pooled five trials (4,153 participants, including CONVINCE and CONTRAST's low-flux comparator) with a median 30-month follow-up: all-cause HR 0.84 (0.74–0.95), about 23 versus 27 deaths per 100, and CV mortality HR 0.78 (0.64–0.96) (Vernooij et al., 2024). Mortality fell across rising achieved convection volume, but achieved dose was not randomized and tracks access quality, tolerance, treatment time and center practice, so the dose–response curve is associational. The Cochrane review (October 2026; 62 studies, 6,897 participants, search to April 2025) found that convective therapy likely reduces all-cause death (RR 0.88, 0.80–0.96; 15 studies, 5,463 participants) and CV death (RR 0.78, 0.66–0.92; 9 studies, 4,761), both moderate certainty downgraded for indirectness, with no clear effect on CV morbidity (RR 1.05), fatigue, access problems or hospitalization (Vernooij et al., 2026). Both syntheses share their key trials with each other and with CONVINCE, so they corroborate rather than replicate.

Evidence map: five randomized trials (CONTRAST, ESHOL, Turkish online HDF, FRENCHIE and CONVINCE with hazard ratio 0.77) feed both the 2024 individual participant data meta-analysis (hazard ratio 0.84) and the 2026 Cochrane review (risk ratio 0.88), highlighted as shared trials; the 2026 target trial emulation and the pending H4RT trial sit apart

The two pooled analyses draw on the same core trials, so they corroborate CONVINCE rather than replicate it independently. The registry study is observational; H4RT is pending.

HDF
Hemodiafiltration
HD
Hemodialysis
HR
Hazard ratio
RR
Risk ratio
IPD
Individual participant data

Real-world evidence

A multinational target trial emulation from a European clinical database (8 countries, 19,539 eligible at day 91 of dialysis, 2014–2019) compared sustained high-volume post-dilution HDF with high-flux HD using inverse probability weighting (Strippoli et al., 2026a). HDF was associated with lower mortality (HR 0.72, 0.67–0.77); weighted 2-year cumulative mortality was 20.6% versus 22.3% (absolute difference 1.7 percentage points), with transplantation as a competing event. It supports transportability to incident patients in routine care, but residual confounding by indication remains, the data come from a single provider network, and several authors are employees of that provider. The stronger relative association in patients with pre-existing CV disease contrasts with randomized subgroup analyses, another reason not to select patients by subgroup.

Patient-reported outcomes

In CONVINCE, all eight Patient-Reported Outcomes Measurement Information System (PROMIS) domains worsened in both arms; a mortality-adjusted joint model showed slower decline with HDF in physical function, patient-perceived cognitive function, pain interference and social participation (Rose et al., 2024). A 2026 prespecified subgroup analysis of 1,211 participants found no convincing heterogeneity; its nominal interactions are hypothesis-generating and should not drive patient selection (Cromm et al., 2026). Perceived cognition is self-reported, so do not promise objective cognitive improvement or symptom relief.

Absolute effects explorer

Converts each source's published figures into events per 1,000 over its own follow-up. Do not compare across sources with different designs, populations or durations.

ArmDeaths per 1,000Source figures

Cost-effectiveness

A trial-based cost-utility analysis from a societal perspective at European prices estimated 2-year incremental cost-effectiveness ratios (ICERs) of €31,898 and €37,344 per quality-adjusted life year (QALY), depending on staffing-cost assumptions, and €27,068 to €36,751 over a lifetime model; much of the extra cost came from dialysis in life-years gained rather than from the HDF session itself (Schouten et al., 2025). These figures do not transfer to Philippine payers, facilities or patients and should not be converted into a local value claim.

Pending

H4RT, a United Kingdom registry-linked randomized trial (ISRCTN10997319), compares high-volume HDF, targeting at least 21 L of substitution fluid adjusted for body surface area, with high-flux HD on a composite of non-cancer death or hospitalization for CV events or infection (Caskey et al., 2022). No peer-reviewed primary results were located as of November 21, 2026. Note that its dose definition (body-size-adjusted substitution volume) differs from CONVINCE's convection volume.

What the guidance bodies say

Strength and certainty are shown separately, in each body's own vocabulary. No Kidney Disease: Improving Global Outcomes (KDIGO) guideline currently grades HDF against high-flux HD.

Body (year)StatementStrengthCertainty
Italian Society of Nephrology, international panel (2026)Online post-dilution HDF to reduce CV mortality in adults on maintenance HDStrong ("we recommend")Moderate; Grading of Recommendations Assessment, Development and Evaluation (GRADE)
Italian Society of Nephrology (2026)High-volume HDF to reduce all-cause mortalityConditional ("we suggest")Moderate
Italian Society of Nephrology (2026)High-volume HDF to slow decline in selected patient-reported domainsConditionalLow
European Renal Association EuDial Working Group (2025)HDF appears associated with improved overall and CV survival provided high convection volumes are achieved; generalizability depends on overall healthConsensus points (mini-Delphi); explicitly not a standard of careUngraded
National Institute for Health and Care Excellence (NICE) NG107, rec. 1.3.11 (2018)For people who choose HD/HDF in center, consider HDF rather than HD"Consider" (weaker NICE wording)Pre-dates CONVINCE

The Italian guidance drew its pooled CV-mortality estimate from the IPD analysis (HR 0.78), while CONVINCE alone could not show a CV-death effect (HR 0.81, wide CI). These answer related questions with different precision and are not in conflict. The guidance frames HDF as a dose-dependent therapy whose implementation requires optimization and monitoring of convection volume, adequate treatment time and blood flow, supporting infrastructure and patient preference (Strippoli et al., 2026b). EuDial treats the CONVINCE figure as a benchmark rather than a proven threshold; no step change in benefit at exactly 23 L has been shown, and body-size indexing remains exploratory (Battaglia et al., 2025).

🔍

This guide's interpretation (renalcarematters.com)

We read the evidence as supporting high-volume post-dilution HDF as a preferred option for adults on thrice-weekly in-center HD whose unit can deliver and audit it, and high-flux HD as fully appropriate care otherwise. We do not regard HDF as an obligation where access, tolerance, unit capability or cost would make delivery inconsistent.

Who the evidence does and does not cover

Population or settingEvidence statusPractical stance
Prevalent adults, thrice-weekly in-center HD, able to reach high volumeDirectly studied (randomized)Offer where the unit is ready
Incident patients (first 90 days)Observational onlyReasonable once stable; prioritize access and volume control
Twice-weekly or incremental HDNo outcome dataDo not extrapolate the survival effect; see incremental dialysis
Catheter or graft accessIncluded but often lower delivered volumeJudge by delivered volume, not by access type alone
Very frail, recurrent intradialytic hypotension, short sessionsUnderrepresentedIndividualize; tolerance and goals first
Children, home HDLimited (EuDial pediatric section; NICE home wording)Specialist decision
Pre-dilution or mixed-dilution HDFNot the mode tested for survivalDo not apply the 23 L benchmark
Asian and lower-resource settingsPoorly represented in trialsExpect transportability questions; audit local delivery
Two panels: well studied, showing an adult on in-center dialysis three times a week with steady access; and less known, with six tiles for twice-weekly dialysis, first weeks of dialysis, children, home dialysis, very frail people, and volume that often stays low

The survival evidence comes mainly from adults on in-center dialysis three times a week who could receive a high volume. For other situations the evidence is thin, and the decision rests on your team and your goals.Ang ebidensiya sa pagkabuhay ay galing pangunahin sa mga nasa hustong gulang na nagda-dialysis sa center tatlong beses isang linggo na kayang tumanggap ng mataas na volume. Sa ibang sitwasyon, kulang ang ebidensiya, at nakasalalay ang desisyon sa iyong team at sa iyong mga layunin.Ang ebidensya sa pagkabuhi gikan kasagaran sa mga hamtong nga nagpa-dialysis sa center tulo ka beses sa usa ka semana nga makadawat og taas nga volume. Sa ubang sitwasyon, kulang ang ebidensya, ug nagdepende ang desisyon sa imong team ug sa imong mga tumong.Ing ebidensya king pamagbiye ibat ya pekamarimla karing matua a mag-dialysis king center makatlu king metung a dominggu a kaya dang tumanggap mataas a volume. King aliwang sitwasyun, kulang ing ebidensya, at makasalalay ing desisyun king team mu at karing layunin mu.

HDF
Hemodiafiltration

Avoid hard eligibility rules based on age, diabetes, baseline CV disease or access type. Subgroup signals across CONVINCE, the IPD analysis and the target trial emulation point in different directions and are exploratory. The question that predicts benefit is practical: can this patient receive high post-dilution volumes session after session without pushing net ultrafiltration or shortening treatment?

Decision pathway and unit readiness

Four decisions, in order
1
Indication and preference. Adult on thrice-weekly maintenance in-center HD, informed about benefit, uncertainty and cost, and interested.
2
Unit readiness. HDF-capable device and compatible disposables; trained staff; validated online production of sterile, nonpyrogenic substitution fluid from ultrapure dialysis fluid; documented microbiological and endotoxin surveillance and disinfection; escalation and fallback pathway.
3
Deliverability. Access performance (achievable blood flow, recirculation), session length, hemodynamic tolerance, hematocrit and anticoagulation that allow repeat high-volume delivery.
4
Cost. Written quote of any premium, monthly total, transport and schedule change acceptable to the patient.
→
Any step unresolved: continue high-flux HD, address the limiting factor and revisit.

Refer to device instructions and local regulatory requirements for water and fluid monitoring limits, sampling frequency, pressure and alarm handling; this guide does not set them. See dialysis water treatment systems for the unit-level background.

Five-step chain from source water through water treatment and ultrapure dialysis fluid to two ultrafilters and sterile substitution fluid entering the blood line, with testing and disinfection checkpoints under every step

Online HDF makes its replacement fluid from ultrapure dialysis fluid passed through extra ultrafilters. Every stage needs regular testing, disinfection and records against the unit's validated limits.

HDF
Hemodiafiltration

Delivering the dose, and auditing it

Prescription principles

Lever diagram: blood flow, effective treatment time and achievable filtration raise the convection volume toward a 23-liter benchmark line, while net ultrafiltration is shown as a barred red lever set only by volume status; common shortfall causes are catheter dysfunction, alarms and clotting, and shortened sessions

Blood flow, effective time and achievable filtration determine convection volume. Net ultrafiltration is set by fluid status and must never be raised to reach the benchmark.

HDF
Hemodiafiltration
TMP
Transmembrane pressure

Troubleshooting low convection volume

PatternLikely causeResponse
Consistently low across sessionsBlood flow limited by access, catheter dysfunction, short timeAccess assessment; extend time; review needle size and placement
Rising TMP, frequent alarmsHigh hematocrit or protein, membrane fouling, excessive filtration fractionReview hemoglobin trend, anticoagulation and membrane; accept a lower substitution rate rather than repeated alarm cycling
Circuit clottingInadequate anticoagulation for post-dilution hemoconcentrationRevise anticoagulation per protocol
Early terminations, intradialytic hypotensionExcess net ultrafiltration, interdialytic gain, cardiac limitsTreat volume and hemodynamics first; do not raise net ultrafiltration to hit volume
Sessions switched to HD fallbackLogistics, machine availability, water system downtimeTrack as a documentation metric; fix the system issue

Follow-up after switching

Review, at a locally chosen interval: delivered time and convection volume per session; prescribed versus achieved net ultrafiltration; intradialytic symptoms and blood pressure; access performance; TMP alarms and clotting; adequacy; and the patient's goals. If convection is repeatedly low, review interruptions, access and tolerance before concluding HDF has "failed." The longitudinal audit tool in the HDx & Convection Toolkit reports the share of documented post-dilution sessions at or above 23 L, while keeping missing, fallback and missed sessions visible.

Philippine practice and costs

PhilHealth Circular 2024-0023 (Revision 2) pays up to ₱6,350 per session for up to 156 hemodialysis sessions per calendar year (up to ₱990,600) for eligible chronic kidney disease stage 5 members and dependents at accredited facilities, with a no-co-payment policy for package items in both public and private units (Philippine Health Insurance Corporation [PhilHealth], 2024a). The circular's guidance document lists hemodiafiltration among premium, non-covered services for which a facility may charge, alongside extra erythropoiesis-stimulating agent doses, additional laboratory tests, dialyzers beyond 32 per year and sessions beyond 156; co-payments must be disclosed on the per-session agreement form (Annex A), and nephrologist professional-fee co-payments are capped at ₱450 per additional service (PhilHealth, 2024b). The underlying HD benefit is therefore preserved for a patient who chooses HDF; the premium is a separate, disclosed charge.

Stacked block for one session: the PhilHealth hemodialysis benefit of up to 6,350 pesos per session and up to 156 sessions a year, topped by a possible facility-specific HDF premium, beside a reminder to get any extra charge in writing

The PhilHealth benefit is preserved for a patient who chooses HDF; any HDF premium is a separate, disclosed charge recorded on the per-session agreement form.

HDF
Hemodiafiltration
PhilHealth
Philippine Health Insurance Corporation

Point-of-care and planning tools

ToolUse
Single-session HDF convectionConvection volume for one session against the CONVINCE benchmark
Delivered HDF session audit (new)Longitudinal view: median volume, share at ≥ 23 L among documented post-dilution sessions, with fallback, missed and undocumented sessions counted separately
HDF cost: patient premium and unit budget (new)Total a quoted premium plus travel; model unit-level incremental budget and break-even receipts
HDF delivery feasibility (new, education)Projected convection volume from effective minutes, mean substitution flow and net ultrafiltration
Dialysis kineticsTMP and filtration fraction
Dialysis prescriptionBlood flow, time and dialysate prescription

Deliberately not built: individual survival prediction, eligibility scoring, pre/post-dilution equivalence and body-size outcome targets, because none is validated for this setting.

Pearls and pitfalls

Evidence ledger and refresh triggers

SourceDesignKey estimateRole
CONVINCE 2023Randomized controlled trial (RCT), n = 1,360All-cause HR 0.77 (0.65–0.93)Lead result
Vernooij 2024IPD meta-analysis, 5 RCTs, n = 4,153HR 0.84 (0.74–0.95); CV HR 0.78Pooled; overlaps CONVINCE
Cochrane 2026Systematic review, 62 studiesRR 0.88 (0.80–0.96); CV RR 0.78Broader convective question; overlaps
Strippoli 2026aTarget trial emulation, n = 19,539HR 0.72; 2-year 20.6% vs 22.3%Real-world support; confounding possible
Rose 2024; Cromm 2026RCT secondary analysesSlower decline in 4 PROMIS domains; no convincing subgroup heterogeneityPatient-reported outcomes
Schouten 2025Trial-based cost-utility€31,898–€37,344 per QALY (2-year)European economics only
H4RTRegistry RCTNot yet publishedPending

Evidence checked November 21, 2026. Recheck on: peer-reviewed H4RT results; new formal recommendations (including any KDIGO statement); evidence for twice-weekly delivery or validated body-size targets; a PhilHealth policy change affecting HDF.

Try the CalculatorsSubukan ang mga CalculatorSulayi ang mga CalculatorSubukan ing reng Calculator
⌬
Delivered HDF Session Audit
Track delivered post-dilution convection volume across sessions against the 23 L benchmark.
Open →
⌬
HDF Cost: Patient Premium and Unit Budget
Total a quoted HDF premium with travel, or model a unit’s incremental budget and break-even.
Open →
⌬
Single-Session HDF Convection
Substitution plus net ultrafiltration for one session, with dilution-mode checks.
Open →
⌬
Dialysis Kinetics
Transmembrane pressure and filtration fraction.
Open →
⌬
Ultrafiltration Rate
Fluid-removal rate per kilogram per hour.
Open →
⌬
Dialysis Adequacy (Kt/V)
Single-pool Kt/V and urea reduction ratio.
Open →
Glossary & abbreviationsTalahulugan at mga daglatTalaan sa mga pulong ug daglatTalatinigan ampo reng daglat terms used in this guide

Abbreviations

CI
Confidence interval.
COVID-19
Coronavirus disease 2019.
CV
Cardiovascular.
ESA
Erythropoiesis-stimulating agent.
GRADE
Grading of Recommendations Assessment, Development and Evaluation, a system for rating certainty of evidence.
HD
Hemodialysis.
HDF
Hemodiafiltration: hemodialysis plus convection with reinfused substitution fluid.
HDx
Expanded hemodialysis using a medium cut-off membrane.
HR
Hazard ratio: relative rate of an event over time.
ICER
Incremental cost-effectiveness ratio.
IPD
Individual participant data.
KDIGO
Kidney Disease: Improving Global Outcomes.
MCO
Medium cut-off (membrane).
NICE
National Institute for Health and Care Excellence (United Kingdom).
NNT
Number needed to treat.
PhilHealth
Philippine Health Insurance Corporation.
PROMIS
Patient-Reported Outcomes Measurement Information System.
QALY
Quality-adjusted life year.
Qb
Blood flow rate through the dialyzer.
RCT
Randomized controlled trial.
RR
Risk ratio.
TMP
Transmembrane pressure.
UF
Ultrafiltration: fluid removed across the membrane.
β2M
β2-microglobulin, a marker middle molecule (about 11.8 kDa).

Terms

Convection
Solute removal carried by water pushed across the membrane.
Convection volume
Substitution volume plus net ultrafiltration in one session.
CONVINCE
2023 randomized trial of high-dose HDF vs high-flux HD in 1,360 adults.
CONTRAST, ESHOL, Turkish online HDF, FRENCHIE
Earlier randomized HDF trials (2012–2017).
Diffusion
Solute movement from higher to lower concentration across the membrane.
EuDial
European Dialysis Working Group of the European Renal Association.
Filtration fraction
Share of blood (or plasma) flow removed as filtrate across the dialyzer.
H4RT
United Kingdom registry-linked randomized trial of high-volume HDF; results pending.
High-flux hemodialysis
Hemodialysis with a membrane permeable to some middle molecules; the comparator in most HDF trials.
Middle molecules
Uremic toxins roughly 0.5–60 kDa that diffusion removes poorly.
Net ultrafiltration
Fluid actually removed from the patient during a session.
Online substitution fluid
Sterile, nonpyrogenic replacement fluid made by the machine from ultrapure dialysis fluid.
Post-dilution / pre-dilution
Substitution fluid added after / before the dialyzer.
Sieving coefficient
Fraction of a solute that passes the membrane with filtered water.
Target trial emulation
An observational analysis designed to mimic a randomized trial.
Ultrapure dialysis fluid
Dialysis fluid meeting very low bacterial and endotoxin limits.
ReferencesMga SanggunianMga TinubdanReng Reperensya 18 sources
  1. Blankestijn, P. J., Vernooij, R. W. M., Hockham, C., Strippoli, G. F. M., Canaud, B., Hegbrant, J., Barth, C., Covic, A., Cromm, K., Cucui, A., Davenport, A., Rose, M., Török, M., Woodward, M., Bots, M. L., & CONVINCE Scientific Committee Investigators. (2023). Effect of hemodiafiltration or hemodialysis on mortality in kidney failure. The New England Journal of Medicine, 389(8), 700–709. https://doi.org/10.1056/NEJMoa2304820
  2. Rose, M., Fischer, F. H., Liegl, G., Strippoli, G. F. M., Hockham, C., Vernooij, R. W. M., Barth, C., Canaud, B., Covic, A., Cromm, K., Cucui, A. M., Davenport, A., Fischer, K. I., Hegbrant, J., Jaha, H., Schappert, A., Török, M., Woodward, M., Bots, M. L., ... CONVINCE Scientific Committee and CONVINCE Investigators. (2024). The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration. Kidney International, 106(5), 961–971. https://doi.org/10.1016/j.kint.2024.07.014
  3. Cromm, K., Fischer, F., Pellegrino, G., Vernooij, R. W. M., Riazy, L., Barth, C., Blankestijn, P. J., Bots, M. L., Canaud, B., Davenport, A., Hegbrant, J., Woodward, M., Rose, M., & Strippoli, G. F. M. (2026). Patient-reported outcomes with high-volume hemodiafiltration versus high-flux hemodialysis across clinical subgroups: Results from the CONVINCE trial. Clinical Journal of the American Society of Nephrology. Advance online publication. https://doi.org/10.2215/CJN.0000001253
  4. Vernooij, R. W. M., Hockham, C., Strippoli, G., Green, S., Hegbrant, J., Davenport, A., Barth, C., Canaud, B., Woodward, M., Blankestijn, P. J., Bots, M. L., CONVINCE Scientific Committee, & HDF Pooling Project Investigators. (2024). Haemodiafiltration versus haemodialysis for kidney failure: An individual patient data meta-analysis of randomised controlled trials. The Lancet, 404(10464), 1742–1749. https://doi.org/10.1016/S0140-6736(24)01859-2
  5. Vernooij, R. W., Strippoli, G. F., Veltkamp, D. M., Nistor, I., Craig, J. C., Saglimbene, V. M., Covic, A. C., & Vecchio, M. (2026). Haemodiafiltration, haemofiltration and haemodialysis for adults with kidney failure. Cochrane Database of Systematic Reviews, 10(10), CD006258. https://doi.org/10.1002/14651858.CD006258.pub3
  6. Strippoli, G. F. M., Tripepi, G., Canaud, B., Stuard, S., Maddux, F. W., Usvyat, L. A., Carioni, P., Savoia, M., Wong, G., & Zoccali, C. (2026a). Hemodiafiltration versus high-flux hemodialysis and risk of mortality: A multinational target trial emulation. Journal of the American Society of Nephrology. Advance online publication. https://doi.org/10.1681/ASN.0000001225
  7. Strippoli, G. F. M., Pellegrino, G., Hegbrant, J., Fabbrini, P., Lentini, P. L. M., Aucella, F., Panichi, V., Gallieni, M., Canaud, B., Davenport, A., Ortiz, A., Ramos, R., Malyszko, J., Kazancıoğlu, R., Kuhlman, M., Ferreira, A. C., Cromm, K., Nigwekar, S., Nissenson, A. R., & De Nicola, L. (2026b). Online hemodiafiltration for kidney failure: Guidance and best clinical practice recommendations from the Italian Society of Nephrology. Journal of Nephrology. Advance online publication. https://doi.org/10.1093/joneph/aajag225
  8. Battaglia, Y., Shroff, R., Meijers, B., Nistor, I., Alfano, G., Franssen, C., Luyckx, V., Liakopoulos, V., Mantovani, A., Baciga, F., Caccia, F., Momentè, C., Davenport, A., Blankestijn, P. J., Covic, A., Combe, C., & Basile, C. (2025). Haemodiafiltration versus high-flux haemodialysis—A consensus statement from the EuDial Working Group of the ERA. Nephrology Dialysis Transplantation, 40(8), 1590–1614. https://doi.org/10.1093/ndt/gfaf024
  9. Tattersall, J. E., Ward, R. A., & EUDIAL group. (2013). Online haemodiafiltration: Definition, dose quantification and safety revisited. Nephrology Dialysis Transplantation, 28(3), 542–550. https://doi.org/10.1093/ndt/gfs530
  10. National Institute for Health and Care Excellence (NICE). (2018). Renal replacement therapy and conservative management (NICE guideline NG107; recommendation 1.3.11). https://www.nice.org.uk/guidance/ng107/chapter/recommendations
  11. Maduell, F., Moreso, F., Pons, M., Ramos, R., Mora-Macià, J., Carreras, J., Soler, J., Torres, F., Campistol, J. M., Martinez-Castelao, A., & ESHOL Study Group. (2013). High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. Journal of the American Society of Nephrology, 24(3), 487–497. https://doi.org/10.1681/ASN.2012080875
  12. Grooteman, M. P. C., van den Dorpel, M. A., Bots, M. L., Penne, E. L., van der Weerd, N. C., Mazairac, A. H. A., den Hoedt, C. H., van der Tweel, I., Lévesque, R., Nubé, M. J., ter Wee, P. M., Blankestijn, P. J., & CONTRAST Investigators. (2012). Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. Journal of the American Society of Nephrology, 23(6), 1087–1096. https://doi.org/10.1681/ASN.2011121140
  13. Ok, E., Asci, G., Toz, H., Ok, E. S., Kircelli, F., Yilmaz, M., Hur, E., Demirci, M. S., Demirci, C., Duman, S., Basci, A., Adam, S. M., Isik, I. O., Zengin, M., Suleymanlar, G., Yilmaz, M. E., Ozkahya, M., & Turkish Online Haemodiafiltration Study. (2013). Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: Results from the Turkish OL-HDF Study. Nephrology Dialysis Transplantation, 28(1), 192–202. https://doi.org/10.1093/ndt/gfs407
  14. Morena, M., Jaussent, A., Chalabi, L., Leray-Moragues, H., Chenine, L., Debure, A., Thibaudin, D., Azzouz, L., Patrier, L., Maurice, F., Nicoud, P., Durand, C., Seigneuric, B., Dupuy, A.-M., Picot, M.-C., Cristol, J.-P., Canaud, B., & FRENCHIE Study Investigators. (2017). Treatment tolerance and patient-reported outcomes favor online hemodiafiltration compared to high-flux hemodialysis in the elderly. Kidney International, 91(6), 1495–1509. https://doi.org/10.1016/j.kint.2017.01.013
  15. Schouten, A. E. M., Fischer, F., Blankestijn, P. J., Vernooij, R. W. M., Hockham, C., Strippoli, G. F. M., Canaud, B., Hegbrant, J., Barth, C., Cromm, K., Davenport, A., Fischer, K. I., Rose, M., Török, M., Woodward, M., Bots, M. L., de Wit, G. A., Frederix, G. W. J., van der Meulen, M. P., & CONVINCE Scientific Committee. (2025). A health economic evaluation of the multinational, randomized controlled CONVINCE trial: Cost-utility of high-dose online hemodiafiltration compared to high-flux hemodialysis. Kidney International, 107(4), 728–739. https://doi.org/10.1016/j.kint.2024.12.018
  16. Caskey, F. J., Procter, S., MacNeill, S. J., Wade, J., Taylor, J., Rooshenas, L., Liu, Y., Annaw, A., Alloway, K., Davenport, A., Power, A., Farrington, K., Mitra, S., Wheeler, D. C., Law, K., Lewis-White, H., Ben-Shlomo, Y., Hollingworth, W., Donovan, J., & Lane, J. A. (2022). The high-volume haemodiafiltration vs high-flux haemodialysis registry trial (H4RT): A multi-centre, unblinded, randomised, parallel-group, superiority study to compare the effectiveness and cost-effectiveness of high-volume haemodiafiltration and high-flux haemodialysis in people with kidney failure on maintenance dialysis using linkage to routine healthcare databases for outcomes. Trials, 23(1), 532. https://doi.org/10.1186/s13063-022-06357-y
  17. Philippine Health Insurance Corporation (PHIC). (2024a). Institutionalization of 156 hemodialysis sessions and coverage expansion (Revision 2) (PhilHealth Circular No. 2024-0023). https://www.philhealth.gov.ph/circulars/2024/PC2024-0023.pdf
  18. Philippine Health Insurance Corporation (PHIC). (2024b). Tamang sagot: Gabay sa tamang pag-unawa sa PhilHealth Circular No. 2024-0023. https://www.philhealth.gov.ph/circulars/2024/TS_PC2024-0023.pdf
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info